Now with Spectral Shift and TRIC, two methods for measuring molecular interactions, Dianthus delivers high-quality data, has the sensitivity to detect more true binders, and requires less assay development to give you results from real-life samples. Immobilization-dependent SPR, and sample-consuming ITC really struggle with affinity screening campaigns for applications involving PROTAC binary and ternary complexes, fragment libraries, and intrinsically disordered proteins. These are precisely the applications where Dianthus excels.
Ready to tackle your challenging affinity screening?
Discover tools you can use
See more related content
NanoTemper Technologies launches Spectral Shift, a breakthrough technology that changes the game for affinity-based screenings
NanoTemper Technologies, announced today the launch of Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery....
25:01Watch this webinar if you’re working in the field of small molecule drug discovery and want to learn how scientists in this field use biophysical tools to search for the most promising lead compounds.
9 Targeted Protein Degradation conferences you don’t want to miss in 2022
With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on recent progress and the latest approaches. You’ll not...
10 terms to help you more easily understand targeted protein degradation
Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...
Targeted protein degradation promises to lead the way to effective drugs for challenging targets
High-throughput determination of protein affinities using unmodified peptide libraries in nanomolar scale
Why so many companies are betting on PROTACs as a superior therapeutic modality
With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...
35:47Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
MST and TRIC technology to reliably study PROTAC binary and ternary binding in drug development
Fast Mek1 hit identification with TRIC technology correlates well with other biophysical methods
56:52Are you working in the field of small molecule drug discovery? Join this webinar to explore the drug discovery workflow and discover tools that can help in your quest for the most promising lead com
59:35Bifunctional degrader molecules (aka PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases, forming a ternary complex that enables ubiquitination and degradation of the target
Protein degraders show promising results in drug development pipelines. See progress candidates have made.
There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...
Is your screening campaign stuck? 3 signs that it’s time to look for an alternative biophysical technology
Most labs dedicated to drug discovery — in big pharma, biopharma, or CROs — make it a priority to have an adequate lineup of instruments for their screening campaigns. They decide on what...
Follow these 7 tips when pipetting small volumes to get consistent assay results
If you’ve ever had to pipette really small volumes, such as what is required in 384-well plates, you’re definitely familiar with the frustrations that come along with it. The concentration alone...
